Reaction Details Report a problem with these data
Target
Prostaglandin E2 receptor EP3 subtype
Ligand
BDBM50205274
Substrate
n/a
Meas. Tech.
ChEMBL_425874 (CHEMBL856878)
Ki
470±n/a nM
Citation
 Sturino, CF; O'Neill, G; Lachance, N; Boyd, M; Berthelette, C; Labelle, M; Li, L; Roy, B; Scheigetz, J; Tsou, N; Aubin, Y; Bateman, KP; Chauret, N; Day, SH; Lévesque, JF; Seto, C; Silva, JH; Trimble, LA; Carriere, MC; Denis, D; Greig, G; Kargman, S; Lamontagne, S; Mathieu, MC; Sawyer, N; Slipetz, D; Abraham, WM; Jones, T; McAuliffe, M; Piechuta, H; Nicoll-Griffith, DA; Wang, Z; Zamboni, R; Young, RN; Metters, KM Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 50:794-806 (2007) [PubMed]  Article 
Target
Name:
Prostaglandin E2 receptor EP3 subtype
Synonyms:
PE2R3_HUMAN | PGE receptor, EP3 subtype | PGE2-R | PTGER3 | Prostaglandin E2 receptor | Prostaglandin E2 receptor EP3 subtype | Prostaglandin E2 receptor EP3 subtype (EP3) | Prostaglandin E2 receptor EP3A subtype (EP3A) | Prostaglandin E2 receptor EP3D subtype (EP3D) | Prostanoid EP3 receptor
Type:
Enzyme
Mol. Mass.:
43335.03
Organism:
Homo sapiens (Human)
Description:
P43115
Residue:
390
Sequence:
MKETRGYGGDAPFCTRLNHSYTGMWAPERSAEARGNLTRPPGSGEDCGSVSVAFPITMLLTGFVGNALAMLLVSRSYRRRESKRKKSFLLCIGWLALTDLVGQLLTTPVVIVVYLSKQRWEHIDPSGRLCTFFGLTMTVFGLSSLFIASAMAVERALAIRAPHWYASHMKTRATRAVLLGVWLAVLAFALLPVLGVGQYTVQWPGTWCFISTGRGGNGTSSSHNWGNLFFASAFAFLGLLALTVTFSCNLATIKALVSRCRAKATASQSSAQWGRITTETAIQLMGIMCVLSVCWSPLLIMMLKMIFNQTSVEHCKTHTEKQKECNFFLIAVRLASLNQILDPWVYLLLRKILLRKFCQIRYHTNNYASSSTSLPCQCSSTLMWSDHLER
  
Inhibitor
Name:
BDBM50205274
Synonyms:
CHEMBL426387 | [(3R)-5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid
Type:
Small organic molecule
Emp. Form.:
C20H16BrClFNO2
Mol. Mass.:
436.702
SMILES:
OC(=O)C[C@H]1CCc2c1n(Cc1ccc(Cl)cc1)c1c(Br)cc(F)cc21
Structure:
Search PDB for entries with ligand similarity: